Courtesy of Benzinga.
Analysts at Credit Suisse downgraded Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) from Neutral to Underperform.
The price target for Sucampo Pharmaceuticals has been raised from $10.00 to $13.00.
Sucampo Pharmaceuticals shares have gained 81.15% over the past 52 weeks, while the S&P 500 index has surged 14.02% in the same period.
Sucampo Pharmaceuticals’ shares fell 3.87% to close at $15.38 on Friday.
Latest Ratings for SCMP
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2015 | Credit Suisse | Downgrades | Neutral | Underperform |
Feb 2015 | Cantor Fitzgerald | Maintains | Buy | |
Oct 2014 | Maxim Group | Upgrades | Hold | Buy |
View More Analyst Ratings for SCMP
View the Latest Analyst Ratings
Posted-In: Credit SuisseDowngrades Analyst Ratings